Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • a day ago

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday, July 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2026 results as well as expectations for the future via conference call on Thursday, July 30, 2026 at 8:30 am ET. A live audio webcast of.

Business Wire • Jul 16, 2026

Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns

I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with strong clinical data and $890 million in Q1 2026 revenue. ALNY's robust cash position ($3.0 billion) and GAAP profitability materially reduce investment risk and support pipeline development.

Seeking Alpha • Jul 16, 2026

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer's Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases. Mivelsiran: An investigational RNAi therapeutic targeting amyloid precursor protein (APP) in develop.

Business Wire • Jul 15, 2026

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.

MarketBeat • Jul 13, 2026

Jim Cramer Says Biotech is The Hottest Group in The Market Right Now

CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.

24/7 Wall Street • Jul 9, 2026

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.

Barrons • Jul 9, 2026

Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?

ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.

Zacks Investment Research • Jul 6, 2026

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

The company has six marketed therapies and several others in late-stage clinical trials. Alnylam has a unique drug delivery system that gives it a deeper moat.

The Motley Fool • Jul 2, 2026

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript

Seeking Alpha • Jun 25, 2026